NCT06924749CompletedPhase 2
Study of of Oxygen Nebulized Inhalation EGCG in Cancer Patients With New Coronary Pneumonia
Study of of Oxygen Nebulized Inhalation EGCG in Cancer Patients With New Coronary：Phase II Clinical Trial
Source: ClinicalTrials.gov · Last updated 28 Nov 2025
Brief summary (registry, in English)
Epigallocatechin-3-gallate (EGCG) is a major polyphenol of green tea that possesses a wide variety of actions, such as anti-inflammatory, anti-fibrotic, pro-apoptotic, anti-tumorous, and metabolic effects via modulation of a variety of intracellular signaling cascades. In addition, preclinical studies have also emphasized the antiviral activity of epigallocatechin-3-gallate (EGCG), including SARS-CoV-2. In previous studies, we found that EGCG can prevent and cure radiation- induced normal tissue damage in tumor patients. In clinical studies, we found that EGCG can prevent and treat radiation-induced acute radiation esophagitis, acute radiation skin injury, acute radiation oral mucositis with high safety. At the same time, the phase I clinical trial designed by us has confirmed the safety and efficacy of EGCG in the treatment of interstitial pneumonia.
- Status (registry)
- Completed
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 111 (actual)
- First submitted
- 22 Aug 2023
- Start date
- 5 Jun 2023
- Primary completion date
- 2 Jun 2024
- Lead sponsor
- Shandong Cancer Hospital and Institute
- NCT number
- NCT06924749
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 111
- From 5 Jun 2023 to the primary completion date, 2 Jun 2024
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Current or recent progresses rapidly and may develop into a Critical illness with coronavirus in a short period of time
- Any condition including medical, emotional, psychiatric, or logistical that, in the opinion of the Investigator would preclude the participant from adhering to the protocol or would increase the risk associated with study participation
- known allergy or hypersensitivity to EGCG
Other
- Caused by other viruses such as cytomegalovirus, as well as pneumocystis pneumonia, pulmonary edema, aspiration pneumonia and acute interstitial pneumonia
Who the study is looking for
- Diagnosed malignant tumors by pathology or cytology
- COVID-19 with a confirmed positive polymerase chain reaction or antigen test result for SARS-CoV-23
- moderate-to-severe COVID-19 pneumonia (defined as any radiographic evidence of pulmonary infiltrates and oxygen saturation \>94% on room air)
- Pulmonary function of the patient can be treated with aerosol inhalation for 7 days
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hanxi Zhao Coordinator of this site? Confirm its status | Jinan | China | Unknown status |
| Shan Dong cancer hospital and institute Coordinator of this site? Confirm its status | Jinan | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.